GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Inventories, Raw Materials & Components

CG Oncology (CG Oncology) Inventories, Raw Materials & Components : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Inventories, Raw Materials & Components?

CG Oncology's inventories, raw materials & components for the quarter that ended in Mar. 2024 was $0.00 Mil.


CG Oncology Inventories, Raw Materials & Components Historical Data

The historical data trend for CG Oncology's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Inventories, Raw Materials & Components Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial - - - - -

CG Oncology Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Inventories, Raw Materials & Components
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines